Introduction: Low-dose computed tomography screening for lung cancer has a high false-positive rate with frequent discovery of indeterminate pulmonary nodules. Noninvasive biomarkers are needed to reduce false positives and improve risk stratification. A retrospective longitudinal evaluation was performed to assess chromosomal aneusomy in sputum by fluorescence in situ hybridization (CA-FISH) in four nested case-control studies.
Introduction
In the context of low-dose computed tomography (LDCT) screening in current and former smokers, the false-positive rate is high (26% at first National Lung Screening Trial [NLST] screening 1 and 13% with Lung-RADS criteria applied to NLST 2 ) and indeterminate nodules are frequently discovered (on 17% to 51% of chest computed tomography [CT] scans). 3 Noninvasive biomarkers are urgently needed to reduce false positives with screening LDCT and to improve risk stratification in those identified to have indeterminate nodules. Biofluids (sputum, blood, and urine) have also been considered to help identify participants who should undergo LDCT. 4, 5 Since 2003, the University of Colorado Lung SPORE has explored a variety of biomarkers in noninvasively collected specimens for early detection of lung cancer. A major effort has been directed toward development of a predictive biomarker applied to sputum epithelial cells on the basis of the common occurrence of chromosomal abnormalities in this disease, mainly copy number variations due to chromosomal aneusomy (CA). A multitarget fluorescence in situ hybridization assay (FISH) has been developed to detect CA in lung cancer and termed CA-FISH. [6] [7] [8] To confirm that CA is an early occurrence, the CA-FISH assay was investigated in premalignant bronchial biopsy specimens. Jonsson et al. 9 reported analyses in high-grade dysplasia lesions of 44 case patients with prevalent cancers compared with in 90 cancer-free controls. Approximately 64% of case patients and only 31% of controls exhibited CA (OR ¼ 4.68, 95% confidence interval [CI]: 1.97-11.04). Massion et al. 10 investigated genomic gains in six loci and two chromosomal regions in high-grade dysplasia lesions in case patients with 27 prevalent lung cancers and 43 controls. With a crude OR of 11 (p < 0.05), the sensitivity of a combination of four probes was 82% and the specificity was 58%. Finally, copy number variation was examined by Nakachi et al. 11 initially by using a genome-wide approach based on single-nucleotide polymorphism microarrays and subsequently confirming by FISH in paired tumor-normal samples obtained by bronchial biopsy or brushings from six case patients with lung cancer, three with carcinoma in situ, and 11 with high-grade dysplasia. Genomic changes were detected in 100% of cancer cases (six of six) and carcinoma in situ cases (three of three), and in 27% (three of 11) of high-grade dysplasia cases. Both well-described and novel alterations were identified across the spectrum of samples.
Copy number variations by FISH have also been detected in sputum epithelial cells, confirming the feasibility of using sputum for this purpose. [6] [7] [8] [12] [13] [14] [15] [16] [17] [18] [19] Table 1 summarizes 11 of these studies according to design, assay platform, conclusions, and criteria for positivity. Most of these investigations used sputum specimens from patients with diagnosed lung cancer and convenience samples of high-risk individuals (e.g., asbestos workers, heavy smokers, and patients with chronic obstructive pulmonary disease [COPD] ) and compared them with specimens from healthy controls or never-smokers. In seven studies, sputum cytology was considered a primary sputum biomarker 6, 7, 12, 13, [15] [16] [17] and the presence of chromosomal abnormalities was evaluated with respect to incremental diagnostic value. Among those studies, six (except for that by Kettunen et al. 12 ) concluded that chromosomal abnormalities improved sensitivity, specificity, or both. Latency of the biomarker was considered in two of the 11 studies 7, 8 and the results suggested that it could be useful for early detection of lung cancer (12 to 18 months before diagnosis). Finally, criteria for positivity ranged from a percentage of abnormal cells among cells sampled (4%-9%) to counts of cells with abnormal targets (from !2 cells up to !6 cells with !2 targets) to three or more SDs above the mean percent of gain or loss.
Validation of biomarkers is challenging. Study design standards for evaluating the predictive accuracy of diagnostic, screening, and prognostic biomarkers have been developed by Pepe et al. 20 Known as the Prospective Specimen Collection, Retrospective Blinded Evaluation (PRoBE) practice standards, their hallmark features are prospective ascertainment of the biomarker before occurrence of the relevant outcome (e.g., disease, recurrence, and progression), randomly selected case patients and controls from a cohort, and blinding when performing the biomarker assay. Testing of the biomarker, either alone or in combination with other biomarkers and clinical data, through the nested casecontrol design must take place within the intended clinical context, and the performance criteria for predictive accuracy must be prespecified.
This article reports on a retrospective longitudinal evaluation incorporating many of the features of a PRoBE design that was performed to assess the potential of a CA-FISH biomarker for early detection of lung cancer.
Materials and Methods

Participant Population
The study population for the testing and validation of a CA-FISH biomarker for lung cancer in nested case-control 21 Briefly, at the time of enrollment, all participants had a cigarette smoking history of at least 30 pack-years and significant COPD but no history of cancer or acute respiratory infection. These patients were asked to collect two consecutive 3-day, early-morning, spontaneous cough sputum specimens in jars containing Saccomanno's fixative (2% carbowax and 50% alcohol) annually. Sputum specimens were stored at room temperature in the Tissue Procurement Core of the University of Colorado SPORE in Lung Cancer. Cohort members were followed by active methods, including telephone and mail contact, and by passive methods, including matching to the Colorado Department of Public Health and Environment Vital Statistics and Central Cancer Registry records. In 2005, 114 case patients with incident lung cancer were identified and matched (according to sex, age, and date of enrollment) with 114 controls who had remained clinically cancer-free for at least 5 years. CA-FISH assay results were obtained from 88% of the case patients and 84% of the controls. From this study, 55 case patients with sputum samples collected within 18 months of diagnosis and 59 controls were included in the current evaluation.
ACRIN/NLST. The NLST was a randomized trial of screening carried out between 2002 and 2010 that compared LDCT with chest radiography (CXR) with regard to reductions in lung cancer mortality.
1 Participants were recruited from the general community between 2002 and 2004. Eligible participants were between 55 and 74 years of age at the time of randomization, had a history of cigarette smoking of at least 30 pack-years, and if former smokers, had quit within the previous 15 years. Persons who had previously received a diagnosis of lung cancer, had undergone chest CT within 18 months before enrollment, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year were excluded. A subgroup of trial PLuSS. The Pittsburgh Lung Screening Study (PLuSS) was a community-based research cohort of current and ex-smokers who were being followed for lung cancer. 22 Briefly, between January 2002 and April 2005, PLuSS used mass mailings and advertisements to enroll 3754 volunteers, mainly from southwestern Pennsylvania, with the following characteristics: (1) age 50 to 79 years; (2) no personal history of lung cancer; (3) current or ex-smoker of at least 10 cigarettes per day for at least 25 years and, if an ex-smoker, stopped smoking not more than 10 years before enrollment; (4) no chest computed tomography within 12 months; and (5) body weight less than 400 pounds. Of the 3754 volunteers enrolled, 92.9% were white and more than 95% had a cigarette smoking history at enrollment of at least 20 pack-years. Sputum samples collected from 60 case patients and 120 controls matched on age, sex, and enrollment were preevaluated; 139 met the criteria to be used for the CA-FISH assay. Successful CA-FISH results were obtained from 139 samples. Of these, samples from 48 case patients and 89 controls were included in this analysis. Two samples were excluded because of inability to verify lung cancer status.
Colorado PuNBaT. The Pulmonary Nodule Biomarker Trial (PuNBaT) is a prospective study that was started in 2010 to establish a cohort of 500 individuals with lung nodules of indeterminate etiology incidentally identified by CT scans; it is currently in the accrual stage. Patients are adults from 18 to 85 years old who were referred to pulmonologists, oncologists, or thoracic surgeons for evaluation of peripheral lung nodules found on CT scan. Repeat CT scans, biopsy, or surgical excision are clinically indicated to determine the etiology of the nodule, and one or more lung nodules must be between 8 mm and 30 mm in the greatest diameter. The main exclusion criteria include (1) lung nodules or masses larger than 30 mm in the greatest dimension; (2) CT evidence of partial or complete obstruction of a lobar bronchus, mainstem bronchus, or trachea; (3) lung nodules with benign calcification; (4) a diagnosis of cancer, with the exception of nonmelanoma skin cancer, within 2 years before study entry; and (5) life expectancy less than 6 months. Participants allowed investigators access to CT scan images and spirometry data, and they provided blood, sputum, urine, and exhaled breath samples over the course of the study. A malignant nodule developed in approximately 33%. Cytological preassessment identified 25 of 36 sputum samples as acceptable for FISH assay. Of these, 13 case patients with lung cancer and 10 controls were included in the current evaluation. Two case patients' cancers that were not lung primaries were excluded from analysis.
Measures
Lung cancer incidence was determined in all studies by following cohort members using active methods (including telephone and mail contact) and passive methods (including matching to the state and national vital statistics records and to the state and hospital cancer registry records). Review of medical, pathology, and tumor-staging records was also performed.
Clinical characteristics such as demographic data, cigarette smoking history, medical history (including pulmonary lung function, COPD status, and personal history of cancer), and current medical problems were ascertained by questionnaire at enrollment. A set of common clinical measures was established to compare risk across the cohorts by using the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Modified 2012 23 lung cancer risk model. For risk fields missing or unavailable, zero added risk was assumed during calculation of the PLCO M2012 risk score, with the exception of education, which was assumed to be post-high school training for all participants.
This evaluation followed most of the PRoBE design principles within each of the clinical contexts represented by the four respective cohort studies, with the exception that the classification criterion was not predefined but rather established within the current evaluation.
On the basis of receiver operating characteristic (ROC) analysis of the CA-FISH score and examination of the PLCO M2012 risk score, participants from these four studies were combined into two groups: a high 
Analytical Methods
The CA-FISH assay was a four-color, four-target panel including genomic sequences encompassing the EGFR and v-myc avian myelocytomatosis viral oncogene homolog (MYC) genes and the 5p15 and centromere 6 regions (FISH panel 1) or the fibroblast growth factor 1 gene (FGFR1) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) genes (FISH panel 2). Specific probe information is presented in the Supplementary Materials and Methods. The CA-FISH assays were performed as previously described 8 ; the details are provided in the Supplementary Materials and Methods. CA-FISH analyses were performed with the Papanicolaou-stained slide (Sigma-Aldrich, St. Louis, MO) to guide the identification of cancer cells in the preparations, and two subpopulations of cells were selected and analyzed (subpopulation 1, which included normalappearing epithelial cells, and subpopulation 2, which included cells with a tumor-like appearance and other cells, as described in Supplementary Materials and Methods). The interpretation criteria were based on copy number gain, and at the participant level, the assay was scored on a four-category scale representing (1) abnormal, (2) probably abnormal, (3) probably normal, and (4) normal, as described and illustrated in Figure 1 .
Statistical Analysis
Sex, COPD status, smoking status and history of tobacco exposure, PLCO M2012 lung cancer risk score, lung function, age, time from sputum collection to lung cancer diagnosis, and lung cancer histologic subtype for cases were compared by using analysis of variance and chisquare tests, as appropriate. For each of the nested case-control studies, a ROC analysis was performed by using logistic regression models with lung cancer status as the outcome and the four-category CA-FISH score as the only predictor. The results of that analysis showed that the discriminatory ability of CA-FISH differed between the two screening cohorts and the two high-risk cohorts but was similar within those two groupings. The best cutoff for CA-FISH was identified within each grouping by using Youden's index. 24 For that cutoff, the sensitivity, specificity, positive likelihood ratio (LR), and negative LR were estimated with their respective 95% CIs. 25 These analyses were also performed separately in the subgroup of participants with COPD.
Results
Characteristics of the participants in each of the nested case-control studies are shown in Table 2 . The study groups are similar in variables such as mean age (62-68 years), mean duration of smoking (43.4-46.5 years), and mean number of cigarettes smoked per day (26.4-31.5). Several differences were observed among the study groups, most notably with regard to pulmonary function (forced expiratory volume in 1 second percent of predicted 42.3-77.8), COPD status (48%-97%), former smoker status (26%-62%), and mean years from quitting smoking (4.7-8.1). Tumor histological subtypes also varied across the cohorts, including nearly equal numbers of squamous cell carcinomas and adenocarcinomas in the Colorado High-Risk Cohort and PLuSS cohort and greater percentages of adenocarcinoma in the Colorado Nodule Cohort and ACRIN samples. The median time elapsed between the collection of sputum samples and clinical diagnosis was shortest in the Colorado Nodule Cohort (À0.7 months) and longest in the PLuSS cohort (8.5 months) with the ACRIN sample and Colorado High-Risk Cohort falling in between (4 and 8 months, respectively). Table 3 shows the distributional properties of the sputum CA-FISH score in each of the four studies. A high percentage of controls in all of the nested case-control studies (ranging from 80% to 95%) exhibited normal FISH scores; only 5% to 20% of controls displayed scores considered abnormal. In the ACRIN/NLST and PLuSS cohorts a low percentage of case patients (16% and 25%, respectively) had abnormal FISH scores, whereas in the other two studies a much higher percentage of case patients (46% and 73%) had abnormal FISH scores.
The ability of the four-category sputum CA-FISH score to discriminate between those participants in whom lung cancer did and did not develop is summarized with the use of ROC curves in Figure 2 . These curves demonstrate that the score appeared to operate similarly in the two highrisk cohorts (Colorado High-Risk Cohort and Colorado Nodule Cohort) and similarly in the two screening cohorts (PLuSS and ACRIN/NLST), and thus, the remainder of the analyses was based on these two groupings.
By applying Youden's index to each of the potential cutoffs for the CA-FISH score, we identified the cutoff of abnormal versus not abnormal as optimal with regard to maximizing the unweighted sum of sensitivity and specificity. When this cutoff was used for the high-risk group, the sensitivity and specificity were 0.67 (95% CI: 0.55-0.78) and 0.94 (95% CI: 0.85-0.98), respectively; for the screening group, the sensitivity and specificity were 0.20 (95% CI: 0.13-0.30) and 0.84 (95% CI: 0.78-0.89), respectively. The respective positive and negative LRs for high-risk participants were 11.66 (95% CI: 4.44-30.63) and 0.34 (95% CI: 0.24-0.48), and the respective positive and negative LRs for screening participants were 1.36 (95% CI: 0.81-2.28) and 0.93 (95% CI: 0.83-1.05). Similar results were observed when only COPD participants were analyzed (data not shown).
Discussion
Lung carcinomas have been known for a long time to frequently exhibit marked chromosome aneusomy reflecting disruptions in the cellular mechanisms ensuring genetic stability. [26] [27] [28] Most common are the defects in the mitotic spindle checkpoints, the abnormal centrosome formation, and failures in the cytokinesis process, which are frequently associated in complex arrangements. 29, 30 We meant to take advantage of this general feature to screen for aneusomic cells in sputum specimen as a biomarker for detection of lung cancer. A similar principle was examined for its potential role as a prognostic marker in lung cancer studies. For instance, increased copy number in EGFR, MYC, 5p15.2, and centromere 6 and deletion in cyclin-dependent kinase inhibitor 2A detected by FISH was associated with poor overall survival rate in lung squamous cell carcinoma. 31 Deletions in 3p detected by comparative genomic hybridization were associated with decreased overall survival in lung squamous cell carcinomas independent of clinicopathological parameters. 32 
Challenges of the CA-FISH Analyses
The CA-FISH assay offers significant challenges for its performance in sputum. First, sputum is a dirty and viscous suspension that includes particles and cellular debris with fluorescent characteristics, which contribute to a high background noise and impair the clear visualization of cells. Second, Saccomanno's fluid is not an optimal long-term fixative and the cell fragility conflicts with the stringency of the protocol necessary to reduce the background noise. It is possible that tumor cells are preferentially destroyed during the procedure because they are known to be less resistant than normal cells to temperature and chemical treatments. Selection of nuclei to score is subjective. We choose to select cells on the basis of features that have documented association with lung carcinoma, such as nucleus of large size, irregular borders, and grainy chromatin texture. We also considered that tumor cells typically stained dimmer with 4,6-diamino-2-phenylindole than did nontumor cells, on account of a looser degree of chromatin condensation. These features seemed to effectively aid in the cell selection, but the manual analytical process is tedious and time-consuming; ideally, an automated or computer-assisted platform should be used. An interesting approach was described by Guber et al. 19 using the automated scanning and analyses by the Duet (BioView, Billerica, MA). Combining FISH variables with parameters from cell morphology, they reached high sensitivity (w92%) and specificity (w80%) in the detection of lung cancer. Moreover, tumor cells are scarce in sputum fluids (<1%), 33 and strategies to enrich the biofluid samples for tumor cells such as those described by Qiu et al. 15 may also be necessary for clinical implementation of the assay.
The limited number of targets that can be simultaneously tested in a FISH assay is also a caveat. Because we are looking for chromosomal numerical changes significantly common in lung cancer, in our efforts we have examined four DNA targets. Nevertheless, screening for a larger panel of probes would very likely increase both the sensitivity and specificity of the CA-FISH assay. An interesting in situ mini-chip approach for FISH probes has been successfully developed and tested in sputum, including sets of seven 17 and of 15 DNA sequences. 18 Although the targets used in those studies do not overlap with ours and mostly covered genomic areas known for being deleted in lung cancer, in both studies the authors demonstrated an improvement of sensitivity and specificity of their test when more targets were simultaneously tested. 
Challenges of Investigating CA-FISH as a Biomarker to Predict/Detect Lung Cancer
After promising performance of CA-FISH as a biomarker for lung cancer in sputum from patients with COPD was observed with the use of a nested case-control design, further evaluation based on PRoBE design principles has highlighted the considerable variability that occurs in lung cancer. Our attempt at a pooled analysis of CA-FISH in sputum in 165 case patients and 254 matched controls illustrates the difficulty in carrying out a standard biomarker validation in the lung cancer environment. Further statistical analysis has illustrated, however, the potential of this marker in patients whose clinical presentation merited specialized care by pulmonologists. This is in contrast to the biomarker's lack of performance in high-risk patients from the general population identified by LDCT screening. In combination, these results support the well-developed idea that lung cancer, like breast, prostate, and colon cancer, represents a family of disease, with LDCT screening yielding patients that followed several different paths of carcinogenesis. This heterogeneity is supported by the preliminary positive performance of CA-FISH in sputum from a small group of patients who were identified to have nodules 8 to 30 mm in diameter and were referred to pulmonologists for further evaluation (as described in Materials and Methods).
Interval between Testing and Clinical Diagnosis
In the screening setting it is critical to consider the optimal interval for applying the biomarker testing. Tests performed too often are unnecessarily expensive, and tests performed too rarely miss the window of opportunity for preclinical diagnosis. Our previous studies have observed abnormal cells in sputum in specimens collected 12 and 18 months before clinical diagnosis, but not in specimens collected long before. 7, 8 Recent data also support a similar conclusion. An investigation of DNA hypermethylation in sputum of asymptomatic participants in the NELSON trial who were at risk for lung cancer 34 analyzed data on the basis of numerous screening interval durations ranging between 1 and 5 years. The results indicated that 2 years was the longest screening interval maintaining the discriminatory capacity of the biomarker. At 3-to 5-year screening intervals, the detection of preclinical disease was significantly reduced. The median time elapsed between sputum sample collection and diagnosis in the current study was on average shorter than 18 months, as shown in Table 2 .
Challenges of Biomarker Validation Analysis
We carried out exploratory analyses to better understand the operating characteristics of CA-FISH as a biomarker for early detection of lung cancer in a variety of cohort settings. In a true PRoBE evaluation, all cutoffs would have been predefined to establish validation. Further work will be needed in the future with one or more external cohorts to accomplish a full PRoBE-style validation study.
As part of PRoBE, the clinical context in which the biomarker will be applied is of critical importance. Our work has clarified that CA-FISH in sputum has potential for reducing diagnostic errors in a clinical setting in which false-positive rates are high (e.g., CT imaging for nodules). More specifically, a positive CA-FISH test result could improve medical decision making in patient management, as illustrated briefly in the next section.
Potential Clinical Utility of CA-FISH in High-Risk Settings
The high positive LR (>10.0) of sputum CA-FISH seen in the high-risk participants in our study indicates that this noninvasive biomarker could be a clinically useful adjunct to LDCT among high-risk patients referred for evaluation for lung cancer, such as the small subset of patients with nodules included in the high-risk group (described in Materials and Methods). As an example, if a hypothetical patient with indeterminate nodules has a pretest (CA-FISH) lung cancer risk of 20%, a positive CA-FISH test result with a positive LR of 11.66 would raise their posttest probability of lung cancer to 78%. This would likely have an impact on clinical management to support biopsy rather than a strategy involving serial imaging to determine nodule growth. In the screening setting, however, the low positive LR (<2.0) of CA-FISH limits its clinical utility both as a prescreening tool and for postscreen risk stratification.
Conclusion
Our evaluation of CA-FISH in sputum suggests the potential of this noninvasive biomarker to complement CT imaging and other diagnostic tests in very high-risk settings, such as the management of individuals with indeterminate nodules. However, the results do not suggest that the biomarker would be useful in low-risk settings, such as screening with LDCT. Whether a similarly high positive LR will be reproducible in a larger high-risk cohort of persons with indeterminate nodules remains to be seen. Prospective assessment of sputum CA-FISH is ongoing in the Colorado Pulmonary Nodule Biomarker Trial supported by the Colorado SPORE in Lung Cancer.
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